ES2636663T3 - Progastrina y patologías hepáticas - Google Patents
Progastrina y patologías hepáticas Download PDFInfo
- Publication number
- ES2636663T3 ES2636663T3 ES11700114.9T ES11700114T ES2636663T3 ES 2636663 T3 ES2636663 T3 ES 2636663T3 ES 11700114 T ES11700114 T ES 11700114T ES 2636663 T3 ES2636663 T3 ES 2636663T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- cdr
- hvh
- hvl
- ahx
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/595—Gastrins; Cholecystokinins [CCK]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Procedimiento para diagnosticar si un paciente presenta múltiples patologías hepáticas, en el que una primera patología hepática ha sido diagnosticada en un paciente, que comprende la etapa de determinación del nivel de progastrina humana (hPG) en una muestra de plasma o suero de dicho paciente, en el que un nivel umbral de progastrina de por lo menos 400 pM indica que dicho paciente probablemente padece por lo menos una patología hepática adicional.
Description
14
- Tabla 3A: Anticuerpos monoclonales anti-PG N-terminales
- Inmunógeno
- Hibridoma(Nº de depósito) MAb Secuencias CDR murinas Secuencias mVH y mVL Secuencias hVH y hVL (proyectadas)
- N1
- 43B9G11 MAb1
- N1
- WE5H2G7 MAb2
- N2
- 6B5B11C10 MAb3 VH CDR 1.3 GYIFTSYW (SEC ID NO:1) VH CDR 2.3 FYPGNSDS (SEC ID NO:2)VH CDR 3.3 TRRDSPQY (SEC ID NO:3)VL CDR 1.3 QSIVHSNGNTY (SEC ID NO:4) VL CDR 2.3 KVS (SEC ID NO:5)VL CDR 3.3 FQGSHVPFT (SEC ID NO:6) mVH.3 (SEC ID NO.12) mVL.3 (SEC ID NO: 13) hVH.3 (SEC ID NO:21)hVL.3 (SEC ID NO:22)
- N2
- 20D2C3G2 MAb4 VH CDR 1.4 GYTFSSSW (SEC ID NO:7) VH CDR 2.4 FLPGSGST (SEC ID NO:8)VH CDR 3.4 ATDGNYDWFAY (SEC ID NO:9)VL CDR 1.4 QSLVHSSGVTY (SEC ID NO:10) VL CDR 2.4 KVS (SEC ID NO:5)VL CDR 3.4 SQSTHVPPT (SEC ID NO:11) mVH.4 (SEC ID NO:14) mVL.4 (SEC ID NO: 15) hVH.4 (SEC ID NO:23)hVL.4 (SEC ID NO:24)
- N2
- 1E9A4A4 (I-4376) MAb15
- N2
- 1E9D9B6 MAb16 VH CDR 1.16 GYTFTSYY (SEC ID NO:39) VH CDR 2.16 INPSNGGT (SEC ID NO:43) VH CDR 3.16 TRGGYYPFDY (SEC ID NO:47) VL CDR 1.16 QSLLDSDGKTY (SEC ID NO:50) VL CDR 2.16 LVS (SEC ID NO:53) VL CDR 3.16 WQGTHSPYT (SEC ID NO:57) mVH.16 (SEC ID NO:61) mVL.16 (SEC ID NO:65) hVH.16a (SEC ID NO:84)hVH.16b (SEC ID NO:86)hVH.16c (SEC ID NO:88)hVL.16a (SEC ID NO:85)hVL.16b (SEC ID NO:87)hVL.16c (SEC ID NO:89)
- N2
- 1C8D10F5 MAb17
- N2
- 1A7C3F11 MAb18
- N2
- 1B3B4F11 MAb19 VH CDR 1.19 GYSITSDYA (SEC ID NO:40) VH CDR 2.19 ISFSGYT (SEC ID NO:44) VH CDR 3.19 AREVNYGDSYHFIDY (SEC ID NO:48) VL CDR 1.19 SQHRTYT (SEC ID NO:51) VL CDR 2.19 VKKDGSH (SEC ID NO:54) VL CDR 3.19 GVGDAIKGQSVFV (SEC ID NO:58) mVH.19 (SEC ID NO:62) mVL.19 (SEC ID NO:66) hVH.19a (SEC ID NO:90)hVH.19b (SEC ID NO:92)hVH.19c (SEC ID NO:94)hVL.19a (SEC ID NO.91)hVL.19b (SEC ID NO:93)hVL.19c (SEC ID NO:95)
- N2
- 1C11F5E8 MAb20
- Inmunógeno N1 = SWKPRSQQPDAPLG-Ahx-Cys-BSA, también representado como (SEC ID NO:25)-Ahx-Cys-BSAInmunógeno N2 = SWKPRSQQPDAPLG-Ahx-Cys-KLH, también representado como (SEC ID NO:25)-Ahx-Cys-KLH
En la tabla 3A, todas las secuencias de aminoácidos se representan utilizando orientación N→C convencional. Para cada inmunógeno, el péptido progastrina se sintetizó conun enlazador C-terminal de un residuo de ácido aminohexanoico (Ahx) seguido de un residuo de cisteína (Cys), que se conjugó después o bien a un vehículo de seroalbúminabovina ("BSA") o bien de hemocianina de lapa californiana ("KLH") por medio de un residuo enlazador de Cys.
16
- Tabla 3B: Anticuerpos monoclonales anti-PGh C-terminales
- Inmunógeno
- Hibridoma(Nº de depósito) MAb Secuencias CDR murinas Secuencias mVH y mVL Secuencias hVH y hVL(proyectadas)
- C1
- 1B4A11D11(I-4371) MAb5
- C1
- 1B6A11F2 (I-4372) MAb6
- C1
- 1B11E4B11(I-4373) MAb7
- C1
- 1C10D3B9 MAb8 VH CDR 1.8 GFTFTTYA (SEC ID NO:37) VH CDR 2.8 ISSGGTYT (SEC ID NO:41) VH CDR 3.8ATQGNYSLDF (SEC ID NO:45) VL CDR 1.8KSLRHTKGITF (SEC ID NO:49) VL CDR 2.8 QMS (SEC ID NO:52) VL CDR 3.8 AQNLELPLT (SEC ID NO:55) mVH.8 (SEC ID NO:59) mVL.8 (SEC ID NO:63) hVH.8a (SEC ID NO:75)hVH.8b (SEC ID NO:77)hVH.8c (SEC ID NO:79)hVL.8a (SEC ID NO:76)hVL.8b (SEC ID NO:78)hVL.8c (SEC ID NO:76)
- C1
- 1D8F5B3 MAb9
- C1
- 1E1C7B4 MAb10
- C1
- 2B4C8C8 (I-4374) MAb11
- C1
- 2B11E6G4(I-4375) MAb12
- C1
- 2C6C3C7 MAb13 VH CDR 1.13 GFIFSSYG (SEC ID NO:38) VH CDR 2.13 INTFGDRT (SEC ID NO:42) VH CDR 3.13 ARGTGTY (SEC ID NO:46)VL CDR 1.13QSLLDSDGKTY (SEC ID NO:50) VL CDR 2.13 LVS (SEC ID NO:53) VL CDR 3.13WQGTHFPQT (SEC ID NO:56) mVH.13 (SEC ID NO:60) mVL.13 (SEC ID NO:64) hVH.1 (SEC ID NO:80)hVH.13b (SEC ID NO:82)hVL.13a (SEC ID NO:81)hVL.13b (SEC ID NO:83)
- C1
- 2H9F4B7 MAb14
- C2
- 1F11F5E10 MAb21
- C2
- 1F11F5G9 MAb22
- C2
- 1A11F2C9 MAb23
- Inmunógeno C1 = KLH-Cys-Ahx-Ahx-QGPWLEEEEEAYGWMDFGRRSAEDEN, también representado como KLH-Cys-Ahx-Ahx-(SEC ID NO:27)Inmunógeno C2 = DT-Cys-Ahx-Ahx-QGPWLEEEEEAYGWMDFGRRSAEDEN, también representado como DT-Cys-Ahx-Ahx-(SEC ID NO:27)
En la tabla 3B, todas las secuencias de aminoácidos se representan utilizando orientación N→C convencional. Para cada inmunógeno, el péptido progastrina sesintetizó con un enlazador Ahx-Ahx-Cys N-terminal, que se conjugó después o bien con un vehículo de hemocianina de lapa californiana ("KLH") o bien de unatoxina de difteria ("DT") por medio de un residuo enlazador de Cys.
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29355710P | 2010-01-08 | 2010-01-08 | |
US293557P | 2010-01-08 | ||
PCT/EP2011/000047 WO2011083089A1 (en) | 2010-01-08 | 2011-01-07 | Progastrin and liver pathologies |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2636663T3 true ES2636663T3 (es) | 2017-10-06 |
Family
ID=43567758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES11700114.9T Active ES2636663T3 (es) | 2010-01-08 | 2011-01-07 | Progastrina y patologías hepáticas |
Country Status (15)
Country | Link |
---|---|
US (1) | US8900817B2 (es) |
EP (1) | EP2542898B8 (es) |
JP (1) | JP5543614B2 (es) |
KR (2) | KR20120102157A (es) |
CN (1) | CN102947707B (es) |
AU (1) | AU2011204652B2 (es) |
BR (1) | BR112012016767A2 (es) |
CA (1) | CA2786437C (es) |
EA (1) | EA023653B1 (es) |
ES (1) | ES2636663T3 (es) |
NZ (1) | NZ601593A (es) |
PL (1) | PL2542898T3 (es) |
SG (1) | SG182332A1 (es) |
WO (1) | WO2011083089A1 (es) |
ZA (1) | ZA201205002B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA028515B1 (ru) * | 2010-07-26 | 2017-11-30 | Ле Лаборатуар Сервье | Способы и композиции для терапии рака печени |
FR2980196B1 (fr) * | 2011-09-16 | 2013-10-04 | Univ Dauvergne Clermont I | Principe actif anticancereux issu de guiera senegalensis |
AU2017204685B2 (en) | 2015-12-31 | 2022-10-13 | Progastrine Et Cancers S.À R.L. | Compositions and methods for detecting and treating gastric cancer |
MA43550A (fr) * | 2015-12-31 | 2018-11-07 | Syncerus S A R L | Compositions et procédés d'évaluation du risque d'apparition d'un cancer |
BR112018013272A2 (pt) | 2015-12-31 | 2018-12-11 | Progastrine Et Cancers S A R L | composições e métodos para detectar e tratar câncer esofágico |
CN108780091A (zh) | 2015-12-31 | 2018-11-09 | 普莱戈斯瑞恩癌症有限责任公司 | 用于检测和治疗卵巢癌的组合物和方法 |
EP3601347B1 (en) | 2017-03-30 | 2021-11-03 | Progastrine et Cancers S.à r.l. | Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule |
WO2018178364A1 (en) | 2017-03-30 | 2018-10-04 | Progastrine Et Cancers S.À R.L. | Compositions and methods for treating lung cancer |
TW201940881A (zh) * | 2018-01-26 | 2019-10-16 | 瑞士商Ecs前胃泌激素公司 | 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術 |
WO2019166499A1 (en) | 2018-02-27 | 2019-09-06 | Ecs-Progastrin Sa | Progastrin as a biomarker for immunotherapy |
RU2761729C1 (ru) * | 2021-04-26 | 2021-12-13 | Вячеслав Леонидович Коробка | Способ оценки риска смерти при циррозе печени |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
CA2384519C (en) | 1991-03-04 | 2006-08-15 | Bayer Corporation | Automated analyzer |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US6063026A (en) | 1995-12-07 | 2000-05-16 | Carbon Based Corporation | Medical diagnostic analysis system |
DE69935977T2 (de) * | 1998-05-15 | 2008-01-10 | Receptor Biologix, Inc., Palo Alto | Vorbeugung und Behandlung von Hypergastrinämie |
US7668661B2 (en) * | 2000-04-28 | 2010-02-23 | Siemens Healthcare Diagnostics Inc. | Liver disease-related methods and systems |
JP2005508838A (ja) * | 2001-03-23 | 2005-04-07 | アフトン コーポレーション | 膵癌の組合せ治療 |
US7381370B2 (en) | 2003-07-18 | 2008-06-03 | Dade Behring Inc. | Automated multi-detector analyzer |
EP2567974A3 (en) * | 2004-09-22 | 2013-05-22 | Cancer Advances, Inc., | Monoclonal antibodies to progastrin |
ES2727306T3 (es) * | 2006-05-22 | 2019-10-15 | Inst Nat Sante Rech Med | Inhibidores de progastrina en el tratamiento del cáncer de colon |
US7854932B2 (en) | 2006-12-19 | 2010-12-21 | The Board Of Regents Of The University Of Texas System | Immunogenic compositions comprising progastrin and uses thereof |
AR078659A1 (es) | 2009-10-16 | 2011-11-23 | Biorealites S A | Anticuerpos monoclonales contra progastrina humana y sus usos |
EA028515B1 (ru) * | 2010-07-26 | 2017-11-30 | Ле Лаборатуар Сервье | Способы и композиции для терапии рака печени |
-
2011
- 2011-01-04 US US12/984,507 patent/US8900817B2/en not_active Expired - Fee Related
- 2011-01-07 AU AU2011204652A patent/AU2011204652B2/en not_active Ceased
- 2011-01-07 NZ NZ601593A patent/NZ601593A/en not_active IP Right Cessation
- 2011-01-07 PL PL11700114T patent/PL2542898T3/pl unknown
- 2011-01-07 EA EA201200997A patent/EA023653B1/ru not_active IP Right Cessation
- 2011-01-07 ES ES11700114.9T patent/ES2636663T3/es active Active
- 2011-01-07 CN CN201180010319.7A patent/CN102947707B/zh not_active Expired - Fee Related
- 2011-01-07 JP JP2012547493A patent/JP5543614B2/ja not_active Expired - Fee Related
- 2011-01-07 CA CA2786437A patent/CA2786437C/en not_active Expired - Fee Related
- 2011-01-07 EP EP11700114.9A patent/EP2542898B8/en active Active
- 2011-01-07 WO PCT/EP2011/000047 patent/WO2011083089A1/en active Application Filing
- 2011-01-07 SG SG2012049151A patent/SG182332A1/en unknown
- 2011-01-07 KR KR1020127020828A patent/KR20120102157A/ko not_active Application Discontinuation
- 2011-01-07 KR KR1020147030287A patent/KR101688106B1/ko active IP Right Grant
- 2011-01-07 BR BR112012016767A patent/BR112012016767A2/pt active Search and Examination
-
2012
- 2012-07-04 ZA ZA2012/05002A patent/ZA201205002B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2786437A1 (en) | 2011-07-14 |
BR112012016767A2 (pt) | 2017-09-05 |
JP5543614B2 (ja) | 2014-07-09 |
EP2542898A1 (en) | 2013-01-09 |
AU2011204652B2 (en) | 2014-04-03 |
EP2542898B8 (en) | 2017-08-09 |
NZ601593A (en) | 2014-08-29 |
JP2013516617A (ja) | 2013-05-13 |
EP2542898B1 (en) | 2017-05-03 |
ZA201205002B (en) | 2013-10-30 |
AU2011204652A1 (en) | 2012-07-26 |
CN102947707B (zh) | 2016-06-01 |
WO2011083089A1 (en) | 2011-07-14 |
KR20120102157A (ko) | 2012-09-17 |
SG182332A1 (en) | 2012-08-30 |
PL2542898T3 (pl) | 2017-10-31 |
US8900817B2 (en) | 2014-12-02 |
CA2786437C (en) | 2020-09-01 |
KR20140132418A (ko) | 2014-11-17 |
EA201200997A1 (ru) | 2013-02-28 |
KR101688106B1 (ko) | 2016-12-20 |
CN102947707A (zh) | 2013-02-27 |
US20110229488A1 (en) | 2011-09-22 |
EA023653B1 (ru) | 2016-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2636663T3 (es) | Progastrina y patologías hepáticas | |
TWI836305B (zh) | 抗garp抗體及其製造方法及用途 | |
PE20070183A1 (es) | Anticuerpos monoclonales anti-trkb | |
ES2525704T3 (es) | Proteínas de unión a antígenos | |
ES2542757T3 (es) | Anticuerpos humanizados específicos de la forma protofibrilar del péptido beta-amiloide | |
AR062065A1 (es) | Anticuerpo humanizado | |
RU2011151069A (ru) | Анти-axl антитело | |
RU2014108047A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака поджелудочной железы | |
RU2015100656A (ru) | Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения | |
NZ581418A (en) | Novel rabbit antibody humanization methods and humanized rabbit antibodies | |
EP3324996A2 (en) | Gdf11 binding proteins and uses thereof | |
PE20090329A1 (es) | Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos | |
AR072985A1 (es) | Tratamiento para una enfermedad autoinmune o trastorno inflamatorio, procedimiento, anticuerpo, proteina de union | |
RU2014134747A (ru) | Гуманизированные антитела, которые распознают альфа-синуклеин | |
RU2010133547A (ru) | Анти-cldn антитела | |
NZ602780A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
NZ724904A (en) | Hybrid immunoglobulin containing non-peptidyl linkage | |
TW200801040A (en) | Binding proteins specific for insulin-like growth factors and uses thereof | |
AR082916A1 (es) | Moleculas de union a 4-1bb | |
CO6331370A2 (es) | Anticuerpos contra el receptor de productos finales de glicosilacion avanzada (rage) y usos de los mismos | |
TW200906856A (en) | Anti-Notch1 NRR antibodies and methods using same | |
PE20110385A1 (es) | Anticuerpo de dominio (dab) que se une a cd28 y no reacciona en forma cruzada con ctla4 | |
EA032189B9 (ru) | Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их | |
CN110914304A (zh) | Cd96抗体、其抗原结合片段及医药用途 | |
CO6220841A2 (es) | Anticuerpos para linfotoxina-alfa |